Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Current Leases (2017 - 2025)

Sonoma Pharmaceuticals has reported Current Leases over the past 9 years, most recently at $146000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 62.22% year-over-year to $146000.0; the TTM value through Dec 2025 reached $146000.0, up 62.22%, while the annual FY2025 figure was $58000.0, 70.71% down from the prior year.
  • Current Leases for Q4 2025 was $146000.0 at Sonoma Pharmaceuticals, up from $88000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $282000.0 in Q3 2022 and troughed at $58000.0 in Q1 2025.
  • A 5-year average of $195050.0 and a median of $224500.0 in 2022 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: soared 85.19% in 2021 and later crashed 70.71% in 2025.
  • Year by year, Current Leases stood at $261000.0 in 2021, then grew by 5.75% to $276000.0 in 2022, then tumbled by 34.42% to $181000.0 in 2023, then tumbled by 50.28% to $90000.0 in 2024, then surged by 62.22% to $146000.0 in 2025.
  • Business Quant data shows Current Leases for SNOA at $146000.0 in Q4 2025, $88000.0 in Q3 2025, and $96000.0 in Q2 2025.